Trials Sponsors Conditions Drugs Pricing

Conditions

Esophageal Cancer Oesophageal Cancer Siewert Type I Adenocarcinoma of Esophagogastric Junction Siewert Type III Adenocarcinoma of Esophagogastric Junction

Keywords

Esophageal CancerEsophagogastric Junction CancerMorbidityMortalitySurgery

Outcome Measures

Primary Outcomes (1)

the type of complications and the incidence of it
the types of complication is classified into as follows: gastrointestinal (anastomotic leak, conduit necrosis/failure, pancreatitis, GI Bleeding, delayed conduit emptying); pulmonary (pneumonia, pleural effusion, pneumothorax, respiratory failure, ARDS, acute aspiration, tracheobronchial Injury); cardiac; thromboembolic; urologic; infection (wound infection; intrathoracic/intra-abdominal abscess; generalized sepsis; other infections); neurologic (recurrent nerve injury, acute delirium) and other (thoracic wound dehiscence, diaphragmatic hernia, chyle leak, reoperation other than for anastomotic leak or conduit necrosis, multiple organ dysfunction syndrome) complications Each complication will be graded according to Clavien-Dindo classification. Re-admission or visiting emergency room will be checked and recorded.
within 90 days after operation

Study Arms (2)

Patients with morbidity and mortality

Patients who suffered from any type of morbidity after surgery

Procedure: Elective Surgery for gastric cancer

Patients without morbidity and mortality

Patients who did not suffer from any type of morbidity after surgery

Procedure: Elective Surgery for gastric cancer

Interventions

Elective Surgery for gastric cancerProcedure

Resection of the esophagus and the gastroesophageal junction via open, laparoscopic or robotic approach

Also known as: Esophageal or Esophagogastric Junction Cancer

Patients with morbidity and mortalityPatients without morbidity and mortality

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

All consecutive patients with clinically documented primary Esophageal or Esophagogastric Junction malignancy (including Siewert I and II) undergoing elective surgery with curative intent - via open, laparoscopic or robotic approach

You may qualify if:

All consecutive patients with clinically documented primary Esophageal or Esophagogastric Junction malignancy (including Siewert I and II) undergoing elective surgery with curative intent - via open, laparoscopic or robotic approach between 18th March 2024 and 18th September 2024

Sponsors & Collaborators

P. Herzen Moscow Oncology Research Institute
Governmentlead
National Medical Research Radiological Centre of the Ministry of Health of Russia
Othercollaborator

Study Sites (18)

N.Alexandrov National Cancer Centre of Belarus

Minsk, Belarus

Bryansk Regional Oncological Hospital

Bryansk, Russia

Cheboksary Republican Clinical Oncology Dispensary

Cheboksary, Russia

M.Sigal Republican Medical Oncology Dispensary

Kazan', Russia

A.Loginov Moscow Clinical Scientific Center

Moscow, Russia

Moscow City Oncology Hospital № 62

Moscow, Russia

P.Herzen Moscow Oncological Research Institute

Moscow, Russia

MeSH Terms

Conditions

Esophageal Neoplasms

Interventions

Elective Surgical Procedures

Condition Hierarchy (Ancestors)

Gastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsDigestive System DiseasesEsophageal DiseasesGastrointestinal Diseases

Intervention Hierarchy (Ancestors)

Surgical Procedures, Operative

Study Officials

Andrey Ryabov, MD, PhD
P.Herzen Moscow Oncological Research Institute
STUDY DIRECTOR
Vladimir Khomyakov, MD, PhD
P.Herzen Moscow Oncological Research Institute
PRINCIPAL INVESTIGATOR
Nuriddin Abdulkhakimov, MD, PhD
P.Herzen Moscow Oncological Research Institute
PRINCIPAL INVESTIGATOR
Pavel Smirnov
P.Herzen Moscow Oncological Research Institute
PRINCIPAL INVESTIGATOR

Enrollment

230 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER GOV
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Head of Department of Thoracoabdominal Oncology

Study Record Dates

First Submitted

February 8, 2024

First Posted

February 26, 2024

Study Start

March 18, 2024

Actual (reported)

Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Patients with morbidity and mortality

Patients without morbidity and mortality

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (18)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

Patients with morbidity and mortality

Patients without morbidity and mortality

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (18)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations